GSK Pauses RSV Vaccine Study In Pregnant Women Over Safety Concern

Delay Could Hand Advantage To Pfizer

 
• By Andrew McConaghie

Enrolment and dosing in a study of up to 10,000 women has been paused, leaving a worrying question mark over the vaccine’s safety.

Pregnant woman vaccination
GSK and Pfizer are both developing matneral RSV vaccines which aim to pass on immunity against the virus to their unborn infants. • Source: Alamy

More from Clinical Trials

More from R&D